Proactive Investors
19 Oct 2026, 15:50 UTC · 49m ago
Silence Therapeutics jumps 59% on Merck takeover
Impact · against what's priced in
Silence Therapeutics is now a takeover target with a defined cash exit of $20 per ADS, creating a significant valuation gap between the current market price and the offer. Kodal Minerals provides a routine update on exploration and production that lacks a material catalyst.
- SLN+1.00
No priced-in read yet
- In context
The agreement for Merck KGaA to acquire the company at $20 per ADS provides a definitive cash exit and a 130% premium over the October 16 close.
Read from the article alone
